US4215106A - Local hemostatic - Google Patents

Local hemostatic Download PDF

Info

Publication number
US4215106A
US4215106A US05/894,248 US89424878A US4215106A US 4215106 A US4215106 A US 4215106A US 89424878 A US89424878 A US 89424878A US 4215106 A US4215106 A US 4215106A
Authority
US
United States
Prior art keywords
hemostatic
solution
hemorrhage
salt
percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/894,248
Inventor
Mikhail G. Voronkov
Ada T. Platonova
Vladislava Z. Annenkova
Galina M. Kononchuk
Valentina B. Kazimirovskaya
Galina S. Ugrjumova
Valentina M. Annenkova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US05/894,248 priority Critical patent/US4215106A/en
Application granted granted Critical
Publication of US4215106A publication Critical patent/US4215106A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Definitions

  • the present invention relates to medicine and, more particularly, to a local hemostatic.
  • the proposed hemostatic serves to arrest parenchymatous hemorrhage in different organs.
  • hemostatics such as hydrogen peroxide, alum and ferric chloride
  • thrombin is limited because of its high cost and side effects it may produce (for example, when thrombin gets into the blood channel it may lead to intravalscular coagulation of the blood).
  • polymer-based synthetic hemostatics include complexes comprising adrenaline and the copolymer of polyvinyl furfural and maleic acid; graft copolymers of cellulose and acrylic acid; cyan-acrylate glue; and oxidized cellulose and its complexes.
  • the foregoing hemostatic preparations are disadvantageous in that they are hard to produce and in that they only act upon separate components of the blood coagulation system.
  • the coagulation time of the best of these preparations is 20 to 60 seconds (the control time being 120 seconds).
  • a local hemostatic comprising an active principle which is the incomplete ferric salt of polyacrylic acid of the formula: ##STR2## in combination with a pharmaceutical solvent which is water or physiological solution (0.85% solution of sodium chloride), the active principle content being 1 to 2 percent by weight.
  • mice were aimed to study the arrest of hemorrhage from incisions in the tail area.
  • the preparation of this invention stopped the bleeding immediately.
  • wounds 0.7 to 1.0 cm long were inflicted upon livers of rats; it took 5 seconds to stop the hemorrhage with the use of the proposed hemostatic.
  • wounds subsequently inflicted in that portion of the liver produced no hemorrhage.
  • No side effects, such as irritation or edema, nor toxic effects were observed in the experimental animals.
  • LD 50 840 mg/kg.
  • the proposed preparation was used to produce local hemostasis in 34 patients. Of these, there were 6 cases of hemophilia due to the extraction of teeth; 2 cases of hemophilia due to the removal of a pseudotumor and osteosynthesis of the hip; 6 cases of other pathological changes in the blood coagulation system (Werlhof's disease, hemolytic anemia, hypoplastic anemia, Marchiafava-Micheli disease); 5 cases of lung operations; 5 cases of operations on the gastroenteric tract; 1 case operated on for a thyrotoxic goiter; 5 cases of cholecystectomy; 3 cases of secondary erosive hemorrhage; and 1 case of cardiovascular insufficiency with nasal bleeding.
  • the hemostatic of the present invention was used to stop diffuse hemorrhage from small vessels at the following stages of an operation:
  • the proposed preparation produces a good hemostatic effect even in patients with a poor blood coagulability. It brings about hemostasis faster than any other hemorrhage arresting drug or technique, and thus considerably reduces losses of blood.
  • the preparation is used in two ways:
  • gauze drains are saturated with 1- or 2-percent solution of the preparation in water or physiological solution, whereupon the drains are dried and autoclaved during 30 minutes at a temperature of 120° C. and a pressure of 1.2 atm.;
  • a dry gauze drainer or a wet tampon is applied to a bleeding area, whereupon an elastic clot is produced and the hemorrhage is stopped.
  • the hemostatic of this invention is a yellow-brownish transparent odorless solution with a pH of 3.0 to 3.4.
  • the proposed preparation is sterilized at 120° C. during 30 minutes. Upon sterilization, the shelf life of the preparation is not less than one year.
  • the preparation's active principle i.e. the incomplete ferric salt of polyacrylic acid, is obtained by polymerizing acrylic acid in an aqueous solution in the presence of this reduction-oxidation system: FeSO 4 .(NH 4 ) 2 SO 4 .6H 2 O/K 2 S 2 O 8 .
  • the polymerization is carried out at a temperature of 25° C.; FeSO 4 .(NH 4 ) 2 SO 4 .6H 2 O is taken in an amount of 0.8 to 2.2 percent by weight.
  • the concentration of acrylic acid in the solution is no more than 20 percent by volume.
  • the resulting viscous red mass is dissolved in water to a concentration of 3 to 4 percent.
  • the incomplete ferric salt of polyacrylic acid (the polymer) is either reprecipitated from the aqueous solution with a saturated aqueous solution of sodium chloride with a subsequent dialysis of the polymer solution aimed to remove the captured NaCl, or is passed through a strong-base anion-exchange resin.
  • the purified polymer solution may be diluted to a concentration of 1 to 2 percent (in this form it is ready for use), or dried at a temperature of 50° C. and the atmospheric pressure.
  • the yield of incomplete ferric salt of polyacrylic acid is 85-95 percent of the theoretical; this salt is a glasslike brittle mass of a orange-brownish color.
  • the molecular weight of the preparation's active principle is 7 ⁇ 10 5 to 5 ⁇ 10 6 .
  • the iron content in the salt is 0.1 to 0.3 percent by weight.
  • the preparation reduces the coagulation time 4 to 12 times, as compared to the best heretofore known preparations; in animals, the coagulation time is 2 to 5 seconds with 120 seconds in control animals;
  • the iron content in the polymer thus produced is 0.11 percent by weight.
  • the iron content in the polymer thus produced is 0.2 percent by weight.
  • Example 2 The process is conducted as in Example 1, but FeSO 4 .(NH 4 ) 2 SO 4 .6H 2 O is taken in an amount of 0.63 g.
  • the iron content in the polymer is 0.3 percent by weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A local hemostatic comprising an active principle which is the incomplete ferric salt of polyacrylic acid of the formula: ##STR1## in combination with a pharmaceutical solvent which is water or physiological solution. The active principle content is 1 to 2 percent by weight.

Description

FIELD OF THE INVENTION
The present invention relates to medicine and, more particularly, to a local hemostatic.
The proposed hemostatic serves to arrest parenchymatous hemorrhage in different organs.
BACKGROUND OF THE INVENTION
The known hemostatics, such as hydrogen peroxide, alum and ferric chloride, are not effective enough, whereas the use of such a natural hemostatic as thrombin is limited because of its high cost and side effects it may produce (for example, when thrombin gets into the blood channel it may lead to intravalscular coagulation of the blood).
There are also known polymer-based synthetic hemostatics. These include complexes comprising adrenaline and the copolymer of polyvinyl furfural and maleic acid; graft copolymers of cellulose and acrylic acid; cyan-acrylate glue; and oxidized cellulose and its complexes.
The foregoing hemostatic preparations are disadvantageous in that they are hard to produce and in that they only act upon separate components of the blood coagulation system. The coagulation time of the best of these preparations is 20 to 60 seconds (the control time being 120 seconds).
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a new effective local hemostatic which would coagulate blood proteins and thus produce a hemostatic effect in both normal and damaged blood coagulation systems.
The foregoing object is attained by providing a local hemostatic comprising an active principle which is the incomplete ferric salt of polyacrylic acid of the formula: ##STR2## in combination with a pharmaceutical solvent which is water or physiological solution (0.85% solution of sodium chloride), the active principle content being 1 to 2 percent by weight.
DETAILED DESCRIPTION OF THE INVENTION
The interaction of the proposed hemostatic with native blood, oxalic plasma, serum and heparinized blood was studied in vitro. In all cases, it took 1 to 2 seconds to produce a firm clot of proteins.
Experiments were also carried out on mice; these were aimed to study the arrest of hemorrhage from incisions in the tail area. The preparation of this invention stopped the bleeding immediately. In another series of experiments, wounds 0.7 to 1.0 cm long were inflicted upon livers of rats; it took 5 seconds to stop the hemorrhage with the use of the proposed hemostatic. After an infiltration of a portion of the liver with a solution of the imcomplete ferric salt of polyacrylic acid, wounds subsequently inflicted in that portion of the liver produced no hemorrhage. No side effects, such as irritation or edema, nor toxic effects were observed in the experimental animals. In the case of rats, LD50 =840 mg/kg.
The proposed preparation was used to produce local hemostasis in 34 patients. Of these, there were 6 cases of hemophilia due to the extraction of teeth; 2 cases of hemophilia due to the removal of a pseudotumor and osteosynthesis of the hip; 6 cases of other pathological changes in the blood coagulation system (Werlhof's disease, hemolytic anemia, hypoplastic anemia, Marchiafava-Micheli disease); 5 cases of lung operations; 5 cases of operations on the gastroenteric tract; 1 case operated on for a thyrotoxic goiter; 5 cases of cholecystectomy; 3 cases of secondary erosive hemorrhage; and 1 case of cardiovascular insufficiency with nasal bleeding.
In all the above cases, the hemostatic of the present invention was used to stop diffuse hemorrhage from small vessels at the following stages of an operation:
(1) incision of the skin;
(2) incision of the subcutaneous fat;
(3) incision of aponeurosis;
(4) arrest of hemorrhage in the bed of a removed spleen;
(5) arrest of hemorrhage in the bed of a removed gallbladder;
(6) arrest of hemorrhage resulting from blunt dissection of commissures in the abdominal cavity;
(7) arrest of hemorrhage resulting from dissection of commissures in the pulmonary and parietal pleura;
(8) arrest of hemorrhage in parenchymatous organs (in the liver in cases of biopsy, as well as in a damaged spleen and lungs);
(9) arrest of hemorrhage during the extraction of teeth.
The proposed preparation produces a good hemostatic effect even in patients with a poor blood coagulability. It brings about hemostasis faster than any other hemorrhage arresting drug or technique, and thus considerably reduces losses of blood.
No adverse side effects are produced both during and after an operation. There are no contraindications to the use of the proposed hemostatic.
The preparation is used in two ways:
(1) gauze drains are saturated with 1- or 2-percent solution of the preparation in water or physiological solution, whereupon the drains are dried and autoclaved during 30 minutes at a temperature of 120° C. and a pressure of 1.2 atm.;
(2) gauze or cotton wool tampons are saturated with the above-mentioned solution and used without drying.
In order to arrest hemorrhage, a dry gauze drainer or a wet tampon is applied to a bleeding area, whereupon an elastic clot is produced and the hemorrhage is stopped.
The hemostatic of this invention is a yellow-brownish transparent odorless solution with a pH of 3.0 to 3.4. The proposed preparation is sterilized at 120° C. during 30 minutes. Upon sterilization, the shelf life of the preparation is not less than one year.
The preparation's active principle, i.e. the incomplete ferric salt of polyacrylic acid, is obtained by polymerizing acrylic acid in an aqueous solution in the presence of this reduction-oxidation system: FeSO4.(NH4)2 SO4.6H2 O/K2 S2 O8. The polymerization is carried out at a temperature of 25° C.; FeSO4.(NH4)2 SO4.6H2 O is taken in an amount of 0.8 to 2.2 percent by weight. The concentration of acrylic acid in the solution is no more than 20 percent by volume. The resulting viscous red mass is dissolved in water to a concentration of 3 to 4 percent. In order to remove the initiator and unreacted acrylic acid, the incomplete ferric salt of polyacrylic acid (the polymer) is either reprecipitated from the aqueous solution with a saturated aqueous solution of sodium chloride with a subsequent dialysis of the polymer solution aimed to remove the captured NaCl, or is passed through a strong-base anion-exchange resin. The purified polymer solution may be diluted to a concentration of 1 to 2 percent (in this form it is ready for use), or dried at a temperature of 50° C. and the atmospheric pressure. The yield of incomplete ferric salt of polyacrylic acid is 85-95 percent of the theoretical; this salt is a glasslike brittle mass of a orange-brownish color. It is readily soluble in water, but is insoluble in alcohols, dioxane, aliphatic hydrocarbons and their chlorine derivatives. The molecular weight of the preparation's active principle is 7·105 to 5·106. The iron content in the salt is 0.1 to 0.3 percent by weight.
The advantages of the proposed local hemostatic are as follows:
(1) the preparation reduces the coagulation time 4 to 12 times, as compared to the best heretofore known preparations; in animals, the coagulation time is 2 to 5 seconds with 120 seconds in control animals;
(2) the preparation effectively coagulates blood proteins, wherefore is can be used with both normal and affected blood coagulation systems;
(3) the preparation of this invention is produced from cheap and readily available raw materials; the production process is carried out in a single step which is well known in the art.
A better understanding of the present invention will be has from a consideration of the following examples which illustrate the production of the preparation's active principle, i.e. incomplete ferric salt of polyacrylic acid.
EXAMPLE 1
28.8 g (0.4 mole) of freshly distilled acrylic acid is dissolved in 120 ml of distilled water. 1.7 g of K2 S2 O8 dissolved in 20 ml of water is added to the solution thus obtained. The reaction mixture is then intensively stirred, as a solution of 0.24 g of FeSO4.(NH4)2 SO4.6H2 O in 2 ml of water is added thereto. The transparent viscous red mass thus produced is dissolved in 1 l of water. In order to remove the unreacted acrylic acid, the incomplete ferric salt of polyacrylic acid (the polymer) is reprecipitated two or three times from an aqueous solution, using a saturated aqueous solution of sodium chloride. The polymer is then again dissolved in water and dialyzed to remove the captured NaCl. The purified solution is dried at 50° C. Instead of salting out, the solution may be passed through an anion exchanger.
The iron content in the polymer thus produced is 0.11 percent by weight.
EXAMPLE 2
28.8 (0.4) mole of freshly distilled acrylic acid is dissolved in 120 ml of distilled water; 1.7 g of K2 S2 O8 dissolved in 20 ml of water is then added to the solution. The reaction mixture is intensively stirred, as a solution of 0.43 g of FeSO4.(NH4)2 SO4.6H2 O is added thereto. After this stage, the process is carried out as in Example 1.
The iron content in the polymer thus produced is 0.2 percent by weight.
EXAMPLE 3
The process is conducted as in Example 1, but FeSO4.(NH4)2 SO4.6H2 O is taken in an amount of 0.63 g. The iron content in the polymer is 0.3 percent by weight.

Claims (2)

What is claimed is:
1. A local hemostatic composition comprising, as active ingredient, a hemostatically effective amount of a water soluble incomplete salt of a polyacrylic acid of the formula ##STR3## said salt prepared by polymerizing acrylic acid in the presence of an reduction-oxidation system, FeSO4.(NH4)2 SO4.6H2 O/K2 S2 O8, to yield a salt having an iron content of 0.1-0.3%, said active ingredient being present in an amount of from 1 to 2% by weight in a pharmaceutical carrier.
2. A method of use of a composition of claim 1 as a hemostatic agent by applying a hemostatically effective amount of said composition to a bleeding or hemorrhaging area in a patient having a bleeding or hemorrhaging area.
US05/894,248 1978-04-07 1978-04-07 Local hemostatic Expired - Lifetime US4215106A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US05/894,248 US4215106A (en) 1978-04-07 1978-04-07 Local hemostatic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/894,248 US4215106A (en) 1978-04-07 1978-04-07 Local hemostatic

Publications (1)

Publication Number Publication Date
US4215106A true US4215106A (en) 1980-07-29

Family

ID=25402796

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/894,248 Expired - Lifetime US4215106A (en) 1978-04-07 1978-04-07 Local hemostatic

Country Status (1)

Country Link
US (1) US4215106A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000251A1 (en) * 1999-06-28 2001-01-04 Dinesh Shantilal Patel Antiseptic and antimicrobial pharmaceutical preparation of feracrylum
WO2001041774A1 (en) * 1999-12-12 2001-06-14 Strathmore Ltd. Haemostatic bactericidal compositions
WO2001074370A1 (en) * 2000-04-03 2001-10-11 Dinesh Shantilal Patel Use of feracryl for the treatment of peptic/duodenal ulcer and/or cholera
EP1408902A2 (en) * 2001-06-22 2004-04-21 Millard Marsden Mershon Compositions and methods for reducing blood and fluid loss from open wounds
ITMO20120180A1 (en) * 2012-07-12 2014-01-13 Enable Innovations S P A SURGICAL GLUE OF SYNTHETIC ORIGIN.
RU2220982C9 (en) * 2001-01-05 2016-04-20 Иркутский институт химии им. А.Е.Фаворского СО РАН, Государственное учреждение "Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра СО РАМН" Argakril - new antiseptic and haemostatic agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB420533A (en) * 1932-06-02 1934-12-03 Ig Farbenindustrie Ag Manufacture of metal salts of polymeric carboxylic acids and the production of shaped articles therefrom
DE2412090A1 (en) * 1973-03-13 1974-09-26 Pat.-Anw., 8000 Muenchen ANTIPEPTIC AGENT AGAINST GASTRODUODENAL SURGERY
US3873588A (en) * 1965-06-08 1975-03-25 Teikoku Hormone Mfg Co Ltd Orally administrable pharmaceutical iron preparation
US4090013A (en) * 1975-03-07 1978-05-16 National Starch And Chemical Corp. Absorbent composition of matter

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB420533A (en) * 1932-06-02 1934-12-03 Ig Farbenindustrie Ag Manufacture of metal salts of polymeric carboxylic acids and the production of shaped articles therefrom
US3873588A (en) * 1965-06-08 1975-03-25 Teikoku Hormone Mfg Co Ltd Orally administrable pharmaceutical iron preparation
DE2412090A1 (en) * 1973-03-13 1974-09-26 Pat.-Anw., 8000 Muenchen ANTIPEPTIC AGENT AGAINST GASTRODUODENAL SURGERY
US4090013A (en) * 1975-03-07 1978-05-16 National Starch And Chemical Corp. Absorbent composition of matter

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dimitrov, Chem Abs, vol. 77, 1972, Ab. No. 116243a. *
Stille, The Nat. Disp., Lea Bros, Phila., 1896, pp. 721, 724, 742, 745-749. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000251A1 (en) * 1999-06-28 2001-01-04 Dinesh Shantilal Patel Antiseptic and antimicrobial pharmaceutical preparation of feracrylum
WO2001041774A1 (en) * 1999-12-12 2001-06-14 Strathmore Ltd. Haemostatic bactericidal compositions
WO2001074370A1 (en) * 2000-04-03 2001-10-11 Dinesh Shantilal Patel Use of feracryl for the treatment of peptic/duodenal ulcer and/or cholera
RU2220982C9 (en) * 2001-01-05 2016-04-20 Иркутский институт химии им. А.Е.Фаворского СО РАН, Государственное учреждение "Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра СО РАМН" Argakril - new antiseptic and haemostatic agent
EP1408902A2 (en) * 2001-06-22 2004-04-21 Millard Marsden Mershon Compositions and methods for reducing blood and fluid loss from open wounds
EP1408902A4 (en) * 2001-06-22 2008-02-13 Millard Marsden Mershon Compositions and methods for reducing blood and fluid loss from open wounds
ITMO20120180A1 (en) * 2012-07-12 2014-01-13 Enable Innovations S P A SURGICAL GLUE OF SYNTHETIC ORIGIN.

Similar Documents

Publication Publication Date Title
Lefer et al. Characterization of a myocardial depressant factor present in hemorrhagic shock
Davidson et al. Experimental study of a novel fibrin sealant for achieving haemostasis following partial hepatectomy
Kocsis et al. Duration of inhibition of platelet prostaglandin formation and aggregation by ingested aspirin or indomethacin
US5773033A (en) Fibrinogen/chitosan hemostatic agents
Fine et al. Traumatic shock: Iv. a study of the problem of the “lost plasma” in hemorrhagic shock by the use of radioactive plasma protein
JP4294436B2 (en) Synthetic soil extract preparation process and pharmaceuticals using it
Teufelsbauer et al. Early activation of hemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis
JPS5838217A (en) Condensed blood plasma derivative
Kolff The artificial kidney—past, present, and future
SU1002356A1 (en) Process for preparing immobilized fibrinolysin
JPS6340546B2 (en)
Jorpes The origin and the physiology of heparin: the specific therapy in thrombosis
Mellanby Thrombase—its preparation and properties
US4215106A (en) Local hemostatic
EP0093489B1 (en) Pharmaceutically active copolymers, process for their preparation and pharmaceutical compositions containing them
US4374830A (en) Platelet aggregating material from equine arterial tissue
EP0468114A2 (en) Soluble haemostatic fabric
RU2118531C1 (en) Pharmaceutical composition for peritoneal dialysis
Zoucas et al. Comparative evaluation of local hemostatic agents in experimental liver trauma: a study in the rat
Lin et al. Chemical burn with cresol intoxication and multiple organ failure
US2589210A (en) Therapeutic compositions
McKay et al. Pathologic study of intravascular coagulation following incompatible blood transfusion in dogs: II. Intra-aortic injection of incompatible blood
Vreim et al. Proportions of dog lung lymph in the thoracic and right lymph ducts
CN113512132A (en) Quick hemostatic hydrogel and preparation method thereof
RU2220982C9 (en) Argakril - new antiseptic and haemostatic agent